8-K: Trevi Therapeutics Provides Clinical Trial Updates and Cash Position Ahead of LifeSci Partners Event

Trevi Therapeutics announced the completion of patient visits in a Phase 2a trial, progress in a Phase 2b trial, and an estimated cash balance of $107.6 million as of December 31, 2024.

Summary

• Trevi Therapeutics has completed the final patient visits for its Phase 2a RIVER trial in refractory chronic cough, with topline results expected in the first quarter of 2025.
• The company's Phase 2b CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough is approximately 80% enrolled, and topline results are expected in the first half of 2025.
• Trevi estimates its cash, cash equivalents, and marketable securities to be $107.6 million as of December 31, 2024, which is expected to provide a cash runway into the second half of 2026.
• The company is developing Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and refractory chronic cough.
• There are no approved therapies for chronic cough in either idiopathic pulmonary fibrosis or refractory chronic cough in the U.S.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with clinical trial progress and a solid cash position, but also acknowledges risks and uncertainties inherent in drug development.

Positives

• The completion of patient visits in the Phase 2a RIVER trial is a positive step towards potential data readout.
• The Phase 2b CORAL trial is progressing well with 80% enrollment, indicating strong progress.
• The estimated cash balance of $107.6 million provides a runway into the second half of 2026, offering financial stability.
• The company is addressing unmet medical needs with Haduvio, as there are no approved therapies for chronic cough in IPF or RCC.

Risks

• The actual cash position may differ from the preliminary estimate of $107.6 million.
• Clinical trial results may not be positive or may not lead to regulatory approval.
• The company's ability to execute its strategy and fund future operations is subject to uncertainties.
• Regulatory authorities' views on the clinical trial data and the development path for Haduvio are uncertain.

Future Outlook

The company anticipates important readouts from its IPF chronic cough and RCC trials in the first half of the year and expects its current cash position to fund operations into the second half of 2026.

Management Comments

• Jennifer Good, President and CEO of Trevi Therapeutics, stated that they look forward to important readouts on their IPF chronic cough and RCC trials in the first half of the year, following strong execution in 2024.
• She also noted that the positive outcomes in the sample size re-estimation analysis of the Phase 2b CORAL trial and in their Human Abuse Potential study were key milestones for their IPF clinical trial and overall development program.

Industry Context

The announcement highlights Trevi's progress in developing a treatment for chronic cough, a significant unmet need in both IPF and RCC, where no approved therapies currently exist. This positions Trevi to potentially capture a significant market share if Haduvio is approved.

Comparison to Industry Standards

• Trevi's focus on chronic cough in IPF and RCC is notable as many companies focus on the underlying diseases rather than the symptomatic treatment of cough.
• The company's progress in Phase 2 trials is consistent with the timelines of other biotech companies developing novel therapeutics.
• The estimated cash runway into the second half of 2026 is a positive sign, as many biotech companies face funding challenges.
• Companies like Bellus Health (BLU) and Merck (MRK) are also developing treatments for chronic cough, but Trevi's approach with Haduvio, targeting both central and peripheral cough mechanisms, is a differentiator.

Stakeholder Impact

• Shareholders may react positively to the clinical trial progress and cash runway.
• Patients with chronic cough in IPF and RCC may benefit from the development of Haduvio.
• Employees may be encouraged by the company's progress and financial stability.

Next Steps

• The company will continue to enroll patients in the Phase 2b CORAL trial.
• Topline results from the Phase 2a RIVER trial are expected in the first quarter of 2025.
• Topline results from the Phase 2b CORAL trial are expected in the first half of 2025.
• Trevi will participate in the 14th Annual LifeSci Partners Corporate Access Event from January 13-15, 2025.

Key Dates

Keywords

Trevi Therapeutics, Haduvio, chronic cough, idiopathic pulmonary fibrosis, refractory chronic cough, clinical trials, Phase 2a, Phase 2b, cash runway, nalbuphine ER